vs

Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and STONERIDGE INC (SRI). Click either name above to swap in a different company.

HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $205.2M, roughly 1.3× STONERIDGE INC). On growth, STONERIDGE INC posted the faster year-over-year revenue change (-6.0% vs -16.5%). HUTCHMED (China) Ltd produced more free cash flow last quarter ($3.4M vs $2.6M).

HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.

Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.

HCM vs SRI — Head-to-Head

Bigger by revenue
HCM
HCM
1.3× larger
HCM
$270.8M
$205.2M
SRI
Growing faster (revenue YoY)
SRI
SRI
+10.5% gap
SRI
-6.0%
-16.5%
HCM
More free cash flow
HCM
HCM
$723.0K more FCF
HCM
$3.4M
$2.6M
SRI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCM
HCM
SRI
SRI
Revenue
$270.8M
$205.2M
Net Profit
$2.0M
Gross Margin
37.7%
16.2%
Operating Margin
-13.2%
-14.4%
Net Margin
0.7%
Revenue YoY
-16.5%
-6.0%
Net Profit YoY
-83.6%
EPS (diluted)
$0.00
$-2.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCM
HCM
SRI
SRI
Q4 25
$270.8M
$205.2M
Q3 25
$210.3M
Q2 25
$277.7M
$228.0M
Q1 25
$324.5M
$217.9M
Q4 24
$218.2M
Q3 24
$213.8M
Q2 24
$305.7M
$237.1M
Q1 24
$239.2M
Net Profit
HCM
HCM
SRI
SRI
Q4 25
$2.0M
Q3 25
$-9.4M
Q2 25
$455.0M
$-9.4M
Q1 25
$11.9M
$-7.2M
Q4 24
Q3 24
$-7.1M
Q2 24
$25.8M
$2.8M
Q1 24
$-6.1M
Gross Margin
HCM
HCM
SRI
SRI
Q4 25
37.7%
16.2%
Q3 25
20.3%
Q2 25
0.1%
21.5%
Q1 25
48.0%
21.2%
Q4 24
19.5%
Q3 24
20.8%
Q2 24
41.1%
22.7%
Q1 24
20.2%
Operating Margin
HCM
HCM
SRI
SRI
Q4 25
-13.2%
-14.4%
Q3 25
-1.6%
Q2 25
-1.3%
-1.1%
Q1 25
-5.0%
-1.5%
Q4 24
-2.0%
Q3 24
0.1%
Q2 24
-9.0%
1.4%
Q1 24
0.1%
Net Margin
HCM
HCM
SRI
SRI
Q4 25
0.7%
Q3 25
-4.5%
Q2 25
163.8%
-4.1%
Q1 25
3.7%
-3.3%
Q4 24
Q3 24
-3.3%
Q2 24
8.4%
1.2%
Q1 24
-2.6%
EPS (diluted)
HCM
HCM
SRI
SRI
Q4 25
$0.00
$-2.76
Q3 25
$-0.34
Q2 25
$0.52
$-0.34
Q1 25
$0.01
$-0.26
Q4 24
$-0.22
Q3 24
$-0.26
Q2 24
$0.03
$0.10
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCM
HCM
SRI
SRI
Cash + ST InvestmentsLiquidity on hand
$1.4B
$66.3M
Total DebtLower is stronger
$93.2M
$180.9M
Stockholders' EquityBook value
$1.2B
$179.8M
Total Assets
$1.8B
$551.2M
Debt / EquityLower = less leverage
0.08×
1.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCM
HCM
SRI
SRI
Q4 25
$1.4B
$66.3M
Q3 25
$54.0M
Q2 25
$1.4B
$49.8M
Q1 25
$836.1M
$79.1M
Q4 24
$71.8M
Q3 24
$54.1M
Q2 24
$802.5M
$42.1M
Q1 24
$48.4M
Total Debt
HCM
HCM
SRI
SRI
Q4 25
$93.2M
$180.9M
Q3 25
Q2 25
$93.4M
Q1 25
$82.8M
Q4 24
$201.6M
Q3 24
Q2 24
$82.1M
Q1 24
Stockholders' Equity
HCM
HCM
SRI
SRI
Q4 25
$1.2B
$179.8M
Q3 25
$251.2M
Q2 25
$1.2B
$260.5M
Q1 25
$759.9M
$253.1M
Q4 24
$245.3M
Q3 24
$271.4M
Q2 24
$740.1M
$270.5M
Q1 24
$277.3M
Total Assets
HCM
HCM
SRI
SRI
Q4 25
$1.8B
$551.2M
Q3 25
$632.1M
Q2 25
$1.8B
$639.4M
Q1 25
$1.3B
$657.4M
Q4 24
$621.6M
Q3 24
$662.5M
Q2 24
$1.3B
$666.7M
Q1 24
$675.4M
Debt / Equity
HCM
HCM
SRI
SRI
Q4 25
0.08×
1.01×
Q3 25
Q2 25
0.08×
Q1 25
0.11×
Q4 24
0.82×
Q3 24
Q2 24
0.11×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCM
HCM
SRI
SRI
Operating Cash FlowLast quarter
$8.2M
$8.8M
Free Cash FlowOCF − Capex
$3.4M
$2.6M
FCF MarginFCF / Revenue
1.2%
1.3%
Capex IntensityCapex / Revenue
1.8%
3.0%
Cash ConversionOCF / Net Profit
4.21×
TTM Free Cash FlowTrailing 4 quarters
$-96.2M
$12.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCM
HCM
SRI
SRI
Q4 25
$8.2M
$8.8M
Q3 25
$3.6M
Q2 25
$-72.9M
$10.7M
Q1 25
$40.3M
$10.9M
Q4 24
$19.2M
Q3 24
$10.8M
Q2 24
$-39.8M
$8.7M
Q1 24
$9.1M
Free Cash Flow
HCM
HCM
SRI
SRI
Q4 25
$3.4M
$2.6M
Q3 25
$-2.7M
Q2 25
$-82.2M
$7.4M
Q1 25
$32.5M
$4.8M
Q4 24
$14.0M
Q3 24
$4.6M
Q2 24
$-49.9M
$1.5M
Q1 24
$3.3M
FCF Margin
HCM
HCM
SRI
SRI
Q4 25
1.2%
1.3%
Q3 25
-1.3%
Q2 25
-29.6%
3.3%
Q1 25
10.0%
2.2%
Q4 24
6.4%
Q3 24
2.2%
Q2 24
-16.3%
0.6%
Q1 24
1.4%
Capex Intensity
HCM
HCM
SRI
SRI
Q4 25
1.8%
3.0%
Q3 25
3.0%
Q2 25
3.3%
1.4%
Q1 25
2.4%
2.8%
Q4 24
2.4%
Q3 24
2.9%
Q2 24
3.3%
3.0%
Q1 24
2.4%
Cash Conversion
HCM
HCM
SRI
SRI
Q4 25
4.21×
Q3 25
Q2 25
-0.16×
Q1 25
3.38×
Q4 24
Q3 24
Q2 24
-1.54×
3.11×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCM
HCM

Segment breakdown not available.

SRI
SRI

Control Devices$51.7M25%
Electronics$38.0M19%
EE$34.2M17%
SE$28.6M14%
NL$24.5M12%
Stoneridge Brazil$14.1M7%
Asia Pacific$13.1M6%

Related Comparisons